Table 4.
Treatment details and outcome of individual patients with CASPR2 antibody-associated disease in the present study
| Parameters | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 |
|---|---|---|---|---|---|---|---|---|
| Duration between onset of symptoms and initiation of treatment (in months) | 3 | 5 | 3 | 1 | 2 | 1 | 3 | 4 |
| Steroids | Y | Y | Y | Y | Y | Y | Y | Y |
| Plasma exchange | Y | Y | Y | N | Y | Y | Y | Y |
| Medication for neuropathic pain | Y | Y | Y | Y | Y | Y | N | N |
| Others | NA | NA | NA | NA | NA | NA | ICU care, ventilation | AED |
| Duration of hospital stay (days) | 23 | 18 | 16 | 8 | 22 | 23 | 90 | 37 |
| Duration of follow-up (months) | 52 | 2 | 22 | 9 | 6 | 20 | * | 30 |
| mRS at admission | 3 | 3 | 3 | 3 | 3 | 5 | 5 | 5 |
| mRS at discharge | 2 | 1 | 1 | 1 | 1 | 4 | 6 | 4 |
| mRS at last follow-up | 0 | 1 | 1 | 0 | 1 | 0 | NA | 0 |
| Improvement at last follow-up/discharge | Y | Y | Y | Y | Y | Y | N (died) | Y |
| Repeat CASPR2 antibody at latest follow-up | Negative | NA | Negative | NA | Negative | Negative | NA | Weakly positive |
| Relapse | N | N | N | N | NA | N | Not applicable | Y |
AED: Antiepileptic drugs; ICU: intensive care unit; N: no; NA: information not available; Y: yes; mRS, modified Rankin score. *Patient died